

Vaia Florou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/267214/publications.pdf>

Version: 2024-02-01

26
papers

708
citations

1307594

7
h-index

794594

19
g-index

28
all docs

28
docs citations

28
times ranked

1055
citing authors

#	ARTICLE	IF	CITATIONS
1	Emerging mechanisms of immunotherapy resistance in sarcomas. Cancer Drug Resistance (Alhambra,) Tj ETQq1 1 0,784314 rgBT /Ov	2.1	15
2	Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer. Current Oncology Reports, 2022, 24, 1107-1112.	4.0	15
3	Intravenous Leiomyomatosis: A Rare Diagnosis With Aggressive Potential. JCO Oncology Practice, 2021, 17, 206-208.	2.9	3
4	The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. Human Vaccines and Immunotherapeutics, 2021, 17, 1935-1939.	3.3	8
5	Real-world outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, 387-387.	1.6	1
6	Considerations for treatment duration in responders to immune checkpoint inhibitors. , 2021, 9, e001901.		69
7	Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. Annals of Translational Medicine, 2021, 9, 1035-1035.	1.7	9
8	Current Management of Angiosarcoma: Recent Advances and Lessons From the Past. Current Treatment Options in Oncology, 2021, 22, 61.	3.0	21
9	Biomarkers of therapeutic response with immune checkpoint inhibitors. Annals of Translational Medicine, 2021, 9, 1040-1040.	1.7	3
10	A 51-year-old man with chronic cough and left hilar prominence. Breathe, 2021, 17, 210018.	1.3	0
11	Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 478-482.	4.9	21
12	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunology, Immunotherapy, 2020, 69, 1177-1187.	4.2	66
13	Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repairâ€œDeficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precision Oncology, 2020, 4, 780-784.	3.0	2
14	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. , 2020, 69, 1177.		1
15	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies: What Is the Path Forward?. Journal of Immunotherapy and Precision Oncology, 2020, 3, 137-139.	1.4	0
16	Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. , 2019, 7, 213.		118
17	Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 837-848.	10.7	262
18	Frameshift mutations (Findel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.. Journal of Clinical Oncology, 2019, 37, 2617-2617.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Angiosarcoma treated with checkpoint inhibitors: A single-institution experience.. Journal of Clinical Oncology, 2019, 37, e22543-e22543.	1.6	0
20	Cancer Immunotherapy in the Immunosuppressed Patients and Its Relevance to Clinical Practice. Journal of Immunotherapy and Precision Oncology, 2019, 2, 127-128.	1.4	1
21	Precision medicine in gastrointestinal stromal tumors. Discovery Medicine, 2019, 28, 267-276.	0.5	6
22	Current and Future Directions for Angiosarcoma Therapy. Current Treatment Options in Oncology, 2018, 19, 14.	3.0	75
23	A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS).. Journal of Clinical Oncology, 2018, 36, 11547-11547.	1.6	8
24	High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid tumor patients treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2018, 36, e24109-e24109.	1.6	0
25	Safety and efficacy of olaratumab added to doxorubicin-based combination chemotherapy in the treatment of advanced soft-tissue sarcoma (STS).. Journal of Clinical Oncology, 2018, 36, e23542-e23542.	1.6	0
26	Latest advances in adult gastrointestinal stromal tumors. Future Oncology, 2017, 13, 2183-2193.	2.4	7